FY2026 Earnings Estimate for EYPT Issued By Chardan Capital

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) – Chardan Capital issued their FY2026 earnings per share (EPS) estimates for shares of EyePoint Pharmaceuticals in a note issued to investors on Monday, March 24th. Chardan Capital analyst D. Gataulin expects that the company will post earnings per share of ($2.82) for the year. Chardan Capital currently has a “Buy” rating and a $33.00 target price on the stock. The consensus estimate for EyePoint Pharmaceuticals’ current full-year earnings is ($2.13) per share.

EYPT has been the topic of a number of other reports. StockNews.com upgraded shares of EyePoint Pharmaceuticals to a “sell” rating in a research note on Friday, March 14th. Citigroup began coverage on shares of EyePoint Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating and a $33.00 price objective on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $22.00 target price on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. One analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. According to MarketBeat, EyePoint Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $26.63.

EyePoint Pharmaceuticals Trading Down 2.5 %

EYPT stock opened at $5.91 on Wednesday. The business’s fifty day moving average price is $6.82 and its 200 day moving average price is $8.24. EyePoint Pharmaceuticals has a 12-month low of $5.54 and a 12-month high of $23.65. The company has a market capitalization of $406.19 million, a PE ratio of -2.96 and a beta of 1.41.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last issued its quarterly earnings data on Wednesday, March 5th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.10). EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. The business had revenue of $11.60 million during the quarter, compared to analysts’ expectations of $11.02 million.

Institutional Investors Weigh In On EyePoint Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Summit Investment Advisors Inc. grew its stake in shares of EyePoint Pharmaceuticals by 39.6% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,838 shares of the company’s stock valued at $51,000 after purchasing an additional 1,940 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of EyePoint Pharmaceuticals in the fourth quarter valued at about $59,000. Virtus ETF Advisers LLC purchased a new stake in EyePoint Pharmaceuticals during the fourth quarter worth about $67,000. AlphaQuest LLC boosted its holdings in EyePoint Pharmaceuticals by 13,246.6% during the fourth quarter. AlphaQuest LLC now owns 9,743 shares of the company’s stock worth $73,000 after buying an additional 9,670 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in EyePoint Pharmaceuticals during the fourth quarter worth about $76,000. 99.41% of the stock is owned by hedge funds and other institutional investors.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.